Cargando…
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent and treat venous thromboembolism. These drugs reduce the risk of clotting at the expense of increasing the...
Autores principales: | Milling, Truman J., Kaatz, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568764/ https://www.ncbi.nlm.nih.gov/pubmed/27575436 http://dx.doi.org/10.1016/j.amjmed.2016.06.009 |
Ejemplares similares
-
Preclinical and clinical data for factor Xa and “universal” reversal agents(,,)
por: Milling, Truman J., et al.
Publicado: (2016) -
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017) -
Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed(,,)
por: Milling, Truman J., et al.
Publicado: (2016) -
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
por: Milling, Truman J., et al.
Publicado: (2016) -
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients
por: Milling, Truman J., et al.
Publicado: (2021)